01
The Biomarker Revolution
Plasma p-tau181, p-tau217, p-tau231, NfL, GFAP, and neuronal/astrocytic EVs now enable blood-based detection of specific pathologies — transforming diagnosis from clinical impression to molecular precision.
COPATHOS
Comorbid Pathologies — Harmonized Optimization of Translational Science
A collaborative consortium for precision diagnostics in complex neurological disease
Building the infrastructure to transform how overlapping neurodegenerative diseases are diagnosed and treated.
The Diagnostic Challenge
The unmet need: overlapping neurodegenerative pathologies
- 50%+
- of Alzheimer's patients at autopsy have mixed pathologies (TDP-43, α-synuclein, vascular)
- 6.9M
- Americans living with Alzheimer's disease, many with undetected comorbid pathologies
- <20%
- of mixed-pathology cases are accurately diagnosed in vivo with current clinical tools
Current diagnostics cannot reliably distinguish coexisting pathologies, leading to suboptimal treatment selection.
Mission
Accelerate the development and clinical implementation of precision diagnostic tools and integrated biomarker panels for differential diagnosis, prognosis, and treatment optimization of complex neurological disease states with overlapping or comorbid pathologies.
Vision
A future in which every patient with neurodegenerative disease receives an accurate molecular diagnosis that distinguishes coexisting pathologies and guides individualized therapy.
Core Values
Scientific Rigor
Evidence held to neuropathological ground truth.
Translational Urgency
Discovery moved to clinic without delay.
Collaborative Innovation
Shared cohorts, data, and standards.
Health Equity
Accessible diagnostics for every population.
Scientific Rationale
Why COPATHOS? The convergence of three revolutions
02
The Genomic Dimension
GWAS and multi-omic profiling reveal shared and disease-specific risk architecture across neurodegeneration: TREM2, GRN, APOE, and MAPT pathways now map the molecular landscape.
03
The Translational Gap
No existing consortium integrates fluid biomarker discovery, genomic/proteomic profiling, neuropathological validation, and clinical trial-ready assay development under one coordinated framework. COPATHOS fills this gap.
Converging into one integrated framework
Four Scientific Pillars
An end-to-end translational framework
Pillar 1
Multi-Omic Discovery
Genomic, proteomic, and lipidomic profiling for disease-specific molecular signatures.
Pillar 2
Fluid Biomarker Innovation
Next-generation blood-based and CSF biomarker panels for differential diagnosis.
Pillar 3
Neuropathological Validation
Biomarker performance verified against autopsy-confirmed diagnoses.
Pillar 4
Translational Deployment
Assay standardization, regulatory strategy, and clinical implementation.
Translational Pipeline
Discovery to deployment, stage by stage
- CC
- TK
- RR
- TV
Founding Leadership
Complete coverage of the translational arc
- RR
Robert A. Rissman, PhD
Co-Director
Biomarker Validation & Translational Pathology
Keck School of Medicine of USC
- CC
Carlos Cruchaga, PhD
Co-Director
Neurogenomics & Multi-Omic Integration
Washington University School of Medicine
- TK
Thomas K. Karikari, PhD
Director
Fluid Biomarker Innovation
University of Pittsburgh
- TV
Timothy E. Van Meter, PhD
Director
Diagnostic Technology & Consortium Operations
BRAINBox Solutions, Inc.
COPATHOS Consortium
Precision Diagnosis. Optimized Treatment. Every Patient.
Partner with us to advance the science of differential diagnosis.